Market Overview:
The global progressive familial intrahepatic cholestasis type 2 treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of progressive familial intrahepatic cholestasis type 2, rising awareness about the disease, and technological advancements in the field of progressive familial intrahepatic cholestasis type 2 treatment. However, factors such as high cost of treatment and lack of reimbursement policies are restraining the growth of this market. The global progressive familial intrahepatic cholestasis type 2 treatment market is segmented on the basis of drug class, application, and region. On the basis of drug class, ursodeoxycholic acid (UDCA) is expected to dominate this market owing to its high efficacy in treating progressive familial intrahepatic cholestasis type 2.
Product Definition:
There is no known cure for Progressive Familial Intrahepatic Cholestasis Type 2. Treatment focuses on relieving symptoms and preventing further liver damage.
Ursodeoxycholic Acid:
Ursodeoxycholic acid, also known as 8-hydroxydeoxycholic acid or 8-OHDCA is a naturally occurring cholinesterase inhibitor that inhibits the enzyme that catalyzes the conversion of choline to acetylcholine. It has been shown to be effective in treating patients with progressive familial intrahepatic cholestasis (PFIC) type 2. The drug was approved by the U.S.
Cholestyramine:
Cholestyramine is a bile acid sequesterant that reduces the amount of cholesterol and other fats in the human body. It is used to treat progressive familial intrahepatic cholestasis type 2 (PFiICC2) which is a rare genetic disorder caused by an abnormal accumulation of bile acids in the liver. The disease has no symptoms at present but may develop them later on resulting into severe health complications for patients.
Application Insights:
Based on application, the global IPF2 treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacy segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of patients suffering from chronic liver diseases at an international level coupled with availability of advanced drugs for treating these diseases within hospitals only.
The increasing prevalence rate of alcoholic liver disease (ALD) has resulted in increased demand for pharmacological interventions that are aimed at reducing the progression rate and mortality associated with this condition. As per data published by WHO, ALD affects approximately 3% to 5% people globally which includes about 1 million individuals across Europe and North America regions alone respectively. Thus, rising number of patients suffering from ALD has created lucrative opportunities for IPF2 treatment across both public and private healthcare facilities worldwide thus contributing significantly towards overall revenue share held by this segment over recent years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of key players, high disease prevalence, and availability of effective treatment methods for FPIC. The U.S., which is one of the most developed nations in terms of healthcare infrastructure and technology, has a higher penetration rate for thesehepatic cholestasis drugs as compared to other countries around the world owing to better accessibility & affordability issues related to healthcare services along with an improved standard medical care system over there.
Asia Pacific is expected to witness lucrative growth during the forecast period due its increasing population coupled with rising disposable income levels that are resulting into increased demand for modern healthcare facilities & products such as medicines; thus fueling revenue generation opportunities across this region over next eight years or so till 2030 AD (as indicated by?). Moreover, growingFPIC patient base mainly from China and India will further boost regional growth during forecast period.
Growth Factors:
- Increasing incidence of Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2)
- Growing awareness about PFIC2 and its treatment options
- Rising demand for better and more effective treatments for PFIC2
- Availability of government funding for research on PFIC2 treatments
- Technological advances that lead to the development of new and better treatments for PFIC
Scope Of The Report
Report Attributes
Report Details
Report Title
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Research Report
By Type
Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Teva, AbbVie, Glenmark Pharmaceuticals, Par Pharmaceuticals, Mylan, Sanofi, Novartis, Akorn, Albireo Pharma, Mirum Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
195
Number of Tables & Figures
137
Customization Available
Yes, the report can be customized as per your need.
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Report Segments:
The global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market is segmented on the basis of:
Types
Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- AbbVie
- Glenmark Pharmaceuticals
- Par Pharmaceuticals
- Mylan
- Sanofi
- Novartis
- Akorn
- Albireo Pharma
- Mirum Pharmaceuticals
Highlights of The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare liver disease that causes the body to not be able to break down bile properly. This can lead to build-up of toxins in the blood and tissues, which can cause serious health problems. PFIC2 treatment typically involves using drugs to help the body break down bile more effectively. Treatment may also involve surgery or other treatments.
Some of the key players operating in the progressive familial intrahepatic cholestasis type 2 treatment market are Teva, AbbVie, Glenmark Pharmaceuticals, Par Pharmaceuticals, Mylan, Sanofi, Novartis, Akorn, Albireo Pharma, Mirum Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size & Forecast, 2018-2028
4.5.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size and Y-o-Y Growth
4.5.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Absolute $ Opportunity
Chapter 5 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Type
5.2.1 Ursodeoxycholic Acid
5.2.2 Cholestyramine
5.2.3 Rifampicin
5.2.4 Late Stage Pipeline Drugs
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Type
9.6.1 Ursodeoxycholic Acid
9.6.2 Cholestyramine
9.6.3 Rifampicin
9.6.4 Late Stage Pipeline Drugs
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Type
10.6.1 Ursodeoxycholic Acid
10.6.2 Cholestyramine
10.6.3 Rifampicin
10.6.4 Late Stage Pipeline Drugs
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Type
11.6.1 Ursodeoxycholic Acid
11.6.2 Cholestyramine
11.6.3 Rifampicin
11.6.4 Late Stage Pipeline Drugs
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Type
12.6.1 Ursodeoxycholic Acid
12.6.2 Cholestyramine
12.6.3 Rifampicin
12.6.4 Late Stage Pipeline Drugs
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Type
13.6.1 Ursodeoxycholic Acid
13.6.2 Cholestyramine
13.6.3 Rifampicin
13.6.4 Late Stage Pipeline Drugs
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Competitive Dashboard
14.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 AbbVie
14.3.3 Glenmark Pharmaceuticals
14.3.4 Par Pharmaceuticals
14.3.5 Mylan
14.3.6 Sanofi
14.3.7 Novartis
14.3.8 Akorn
14.3.9 Albireo Pharma
14.3.10 Mirum Pharmaceuticals
